Menu
Book A call

WHO
WE
ARE

IT’S TIME TO HEAL

Numinus exists to help the world heal, starting with addressing the global crisis in mental health by harnessing the power and promise of psychedelic medicine. Through our integrated model, we are actively contributing to the body of primary and clinical psychedelic research while delivering best-in-class therapeutic protocols across our clinics.

Going beyond breakthroughs

We understand that psychedelics are powerful medicines, but not magic pills. We understand that they can profoundly change lives, families, and communities, and that success requires more than just a breakthrough experience—it also takes careful, sensitive attention to every individual’s story, mindful preparation, and a grounded, realistic plan for what comes after.

Multidisciplinary expertise with human-centred care

Numinus boasts a diverse and interdisciplinary team of professionals, from physicians and psychiatrists to mindfulness teachers, nurses and psychotherapists, researchers and technicians. Our protocols are backed by rigorous science, and delivered by a team that understands that even the best tools still require genuine human care to be effective.

Curiosity and humility

At the core of what we do at Numinus is a deep sense of curiosity and humility about everything we encounter. We know that psychedelics, mindfulness, and embodied practices are not new tools, but rather owe a debt to some very old ways of being and caring for one another. We’re working every day to honour that wisdom and those traditions, and integrating it with the best that modern science has to offer.

OUR CLINIC TEAM

1 2 3 13

RECENT COMPANY UPDATES

News
8 MIN READ
Dr. Reid Robison Interviewed by Daily Hive
In an interview with The Daily Hive, Dr. Reid Robison, Chief Clinical Officer at Numinus, discusses the potential benefits of psychedelic-assisted therapy for treating conditions such as depression, anxiety, and […]
January 9, 2023
News
What Are the Benefits of Microdosing? | Goop
Numinus's VP of Psychedelic Neurology, Dr. Evan Lewis, chats with  Kelly Martin from Goop to discuss microdosing’s current research findings and the potential for it to be a treatment in neurological disorders.
August 12, 2022
News
Meet Payton Nyquvest | Psychedelia Magazine
Our CEO Payton Nyquvest goes in depth with Tom Zuber in the 2021 winter edition of Psychedelia magazine. Read the full feature here as they discuss everything from what drove Payton to found Numinus to what’s in store for the near future.  
December 8, 2021
News
Numinus Completes Acquisition of Neurology Centre of Toronto
Acquisition strengthens clinic portfolio for mental health treatment using psychedelic-assisted therapies VANCOUVER, BC, Sept. 23, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments […]
September 23, 2021
News
Numinus to Participate in Upcoming Investor Conferences in September 2021
VANCOUVER, BC, September 2, 2021 — Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced […]
September 2, 2021
News
Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology
VANCOUVER, BC, July 29, 2021 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its fiscal […]
July 29, 2021
News
MDMA-Assisted Therapy for PTSD: In conversation with Rick Doblin & Payton Nyquvest
Why is real world evidence important for psychedelic research and how do therapy and psychedelics work together? MAPS founder, Rick Doblin, and our CEO, Payton Nyquvest share their thoughts, our […]
July 16, 2021
News
Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD
Real-world study expands access to MDMA-assisted therapy for patients with PTSD and concurrent disorders and will provide data on a regulated model for MDMA-assisted therapy VANCOUVER (July 12, 2021) – Numinus […]
July 12, 2021
News
Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology
NCT’s treatment of neurological disorders combined with Numinus’ leadership in psychedelic-assisted therapy will offer opportunity to treat a range of chronic neurological conditions and common concurrent mental health challenges VANCOUVER […]
July 6, 2021
News
Numinus Announces Update to Escrow Release Schedule
VANCOUVER, BC, June 25, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce […]
June 25, 2021
News
Numinus Announces Grant of Stock Options
VANCOUVER, BC, June 24, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announces that it has […]
June 24, 2021
News
Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species
Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable VANCOUVER (June 24, 2021) – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care […]
June 24, 2021
News
Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange
VANCOUVER, BC, June 18, 2021 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce […]
June 18, 2021
News
‘People are desperate to heal’: The push for psychedelic-assisted therapy in Canada
  Numinus was featured on Global TV’s “The New Reality” show! The show details the potential for psychedelic-assisted psychotherapy to treat a number of mental health conditions. It features interviews […]
June 15, 2021
News
FR: Numinus Wellness annonce le recrutement de dirigeants clés pour soutenir sa croissance rapide et l’innovation
Des gestionnaires chevronnés pourvoient des postes de direction dans le développement des affaires, les fusions et acquisitions, l’exploitation et la conception des cliniques, et les communications institutionnelles VANCOUVER, C.-B., Le […]
May 13, 2021
News
Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation
Cliquez ici pour la version française Experienced executives fill senior roles in business development, M&A, clinic operations and design, and corporate communications VANCOUVER, BC, May 13, 2021 - Numinus Wellness Inc. ("Numinus" or […]
May 13, 2021
News
FR: Numinus Wellness et Optimi Health soumettent un extrait de psilocybine entièrement naturelle à Santé Canada en vue d’une demande d'essai pré-clinique
Le partenariat vise à offrir des capsules psychédéliques pour une étude posologique dans un essai clinique humain VANCOUVER (le 11 mai 2021) – Numinus Wellness Inc. (“Numinus” ou la “Société”) (TSXV: NUMI), une […]
May 11, 2021
News
Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application
Cliquez ici pour la version française Partnership Aimed at Delivering Psychedelic Capsule for Dosing Study in Human Clinical Trial VANCOUVER (May 11, 2021) – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), […]
May 11, 2021
News
Numinus celebrates Mental Health Week 2021
Mental illness is invisible to the eye — but it’s no less real than physical injury. Now, more than ever, we need to reprioritize and recognize that millions of people […]
May 10, 2021
News
Numinus builds on strong MAPS Phase 3 trial results through Compassionate Access Trial of MDMA for PTSD
Yesterday, MAPS announced significant, positive results for their Phase 3 clinical trial of MDMA-assisted therapy for PTSD - a major contribution to a growing body of evidence supporting this treatment. […]
May 10, 2021
News
Numinus Congratulates MAPS on Phase 3 Clinical Trial of MDMA for severe PTSD
1 in 11 Canadians will suffer from PTSD in their lifetime. We urgently need new approaches to mental health care - and now we’re getting closer. Numinus and Dr. Devon […]
May 10, 2021
News
FR: Numinus félicite MAPS pour son essai clinique de phase 3 révélant des bienfaits significatifs de la thérapie assistée par MDMA dans le traitement du SSPT grave
Une collaboration entre Numinus et l’Association multidisciplinaire pour les études psychédéliques réalisera un essai de suivi d’accès compassionnel dans un contexte réel à Vancouver, au Canada VANCOUVER (Le 12 mai 2021) […]
May 10, 2021
News
Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD
Cliquez ici pour la version française Numinus and Multidisciplinary Association for Psychedelic Studies collaboration will conduct follow-on Compassionate Access trial in real-world setting in Vancouver, Canada VANCOUVER (May 10, 2021) – Numinus […]
May 10, 2021
News
Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC
Events subsequent to quarter end include $40.25 million financing and Phase 1 clinical trial VANCOUVER, BC, April 29, 2021 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental […]
April 29, 2021
News
FR: Numinus annonce un essai clinique de phase 1 sur l’extraction naturelle de champignons psilocybe préparée au laboratoire de la société
L’essai clinique évaluera la sécurité et les propriétés psychoactives de la psilocybine naturelle extraite et formulée dans le laboratoire de 7 000 pieds carrés en Colombie-Britannique, au Canada VANCOUVER, C.-B., […]
April 26, 2021
News
Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company Lab
Cliquez ici pour la version française Clinical trial will evaluate safety and psychoactive properties of natural Psilocybin product extracted and formulated at 7,000-square-foot laboratory in British Columbia, Canada VANCOUVER (April […]
April 26, 2021
News
Numinus Announces Listing of Warrants and Change of Trading Symbol for Previously Listed Warrants
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia, April 26, 2021, Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a […]
April 26, 2021
News
There Is a Lot of Fungus Among Us
Coffee for immune support. Supplements for inflammation. And psychedelics promising relief from serious ailments. Mushrooms are everywhere, and investors are paying attention. Read the article on NYT
April 24, 2021
News
FR: Numinus annonce la clôture d’un financement par voie de prise ferme de 40 M$
LE PRÉSENT COMMUNIQUÉ DE PRESSE EST DESTINÉ À ÊTRE DIFFUSÉ AU CANADA UNIQUEMENT ET N’EST PAS DESTINÉ À ÊTRE DISTRIBUÉ AUX AGENCES DE PRESSE AMÉRICAINES NI À ÊTRE DIFFUSÉ AUX […]
March 19, 2021
News
Numinus Announces Closing of $40-Million Bought Deal Financing
Cliquez ici pour la version française THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN […]
March 19, 2021
News
FR: Numinus Wellness Inc. annonce un placement public de 30 M$ par voie de prise ferme
LE PRÉSENT COMMUNIQUÉ DE PRESSE EST DESTINÉ À ÊTRE DIFFUSÉ AU CANADA UNIQUEMENT ET N'EST PAS DESTINÉ À ÊTRE DISTRIBUÉ AUX AGENCES DE PRESSE AMÉRICAINES NI À ÊTRE DIFFUSÉ AUX […]
March 15, 2021
News
Numinus Wellness Inc. Announces Upsized Bought Deal Public Offering to $35 Million
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, […]
March 15, 2021
News
Numinus Wellness Inc. Announces $30 Million Bought Deal Public Offering
Cliquez ici pour la version française THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN […]
March 15, 2021
News
FR: Numinus agrandira son laboratoire de recherche ultramoderne sur les psychédéliques
Numinus Bioscience ajoutera un espace de recherche, améliorera les services contractuels, accélèrera le développement de la propriété intellectuelle et augmentera la capacité d’approvisionnement de psychédéliques VANCOUVER (Le 9 mars 2021) — Numinus Wellness […]
March 9, 2021
News
Numinus to expand state-of-the-art psychedelics research laboratory
Cliquez ici pour la version française Numinus Bioscience adds research space, enhances contract services, accelerates IP development and increases psychedelic supply capacity VANCOUVER (March 9, 2021) – Numinus Wellness Inc. ("Numinus" or the […]
March 9, 2021
News
FR: Les laboratoires Numinus au premier plan de la recherche mondiale sur les psychédéliques suite aux autorisations réglementaires
Numinus Bioscience ajoute à sa licence la kétamine et le LSD pour produire, assembler et vendre une gamme étendue de composés psychédéliques VANCOUVER (Le 4 mars 2021) — Numinus Wellness […]
March 4, 2021
News
Regulatory Approvals Place Numinus Lab at the Forefront of Global Psychedelics Research
Cliquez ici pour la version française Numinus Bioscience adds Ketamine and LSD to licence to produce, assemble and sell a wide variety of psychedelic compounds VANCOUVER (March 4, 2021) – Numinus […]
March 4, 2021
News
FR: Numinus et Syreon fournissent une mise à jour concernant les essais cliniques à accès compassionnel sur la psilocybine
Des progrès significatifs ont été réalisés, alors que l’étude PRIME, parrainée par Numinus, sur la psychothérapie assistée par psilocybine pour les troubles liés à la consommation d’opiacés, de stimulants et/ou […]
March 2, 2021
News
Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update
Cliquez ici pour la version française Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage VANCOUVER (March 2, 2021) […]
March 2, 2021
News
Numinus Wellness looking to position itself at the forefront of psychedelics for healing and wellness
Through its Bioscience lab, Numinus is the first public company in Canada to receive a licence to produce and extract psilocybin from mushrooms. Click here to read more.
February 19, 2021
News
Numinus Wellness's trial for MDMA-assisted therapy is in pre-implementation stage
The study, which is in collaboration with MAPS Public Benefit Corporation (MAPS PBC), subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), has successfully transitioned into the 'pre-implementation stage' at […]
February 18, 2021
News
FR: Numinus annonce des avancées dans les essais cliniques à accès compassionnel pour la thérapie assistée par MDMA en collaboration avec MAPS Public Benefit Corporation
Les essais cliniques entrent en phase préparatoire après avoir franchi plusieurs jalons importants en vue d’étendre l’accès aux patients souffrant de SSPT (Syndrome de stress post-traumatique) VANCOUVER (Le 18 février […]
February 18, 2021
News
Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation
Cliquez ici pour la version française Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD VANCOUVER (February 17, 2021) – Numinus Wellness Inc. ("Numinus" or […]
February 17, 2021
News
FR: Numinus Wellness finalise l'acquisition de Mindspace Wellbeing, basée à Montréal
Cette acquisition renforce la présence de Numinus tout en améliorant le paysage des thérapies assistées par psychédéliques au Canada VANCOUVER, (C.-B.), le 8 février 2021 – Numinus Wellness Inc. ("Numinus" ou la "société") […]
February 8, 2021
News
Numinus Wellness Completes Acquisition of Montreal-based Mindspace Wellbeing
Cliquez ici pour la version française Acquisition expands Numinus’ presence while improving psychedelic-assisted therapy landscape in Canada VANCOUVER, BC – February 8, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: […]
February 8, 2021
News
Numinus Engages Native Ads Inc. for Digital Media Services
VANCOUVER (February 5, 2021) – Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of […]
February 5, 2021
News
Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts
Key milestones met in ongoing trials , expanding national footprint, and enhanced research capabilities ensure Numinus’ continued growth VANCOUVER, BC – January 29, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: […]
January 29, 2021
News
FR: Numinus Wellness fait avancer la recherche axée sur la découverte en matière de psychédéliques grâce au spectromètre de masse Orbitrap Exploris 120
L’acquisition de cet instrument de pointe de Thermo Fisher Scientific fera grandement progresser la recherche sur les psychédéliques et accélérera les capacités de test standardisé pour les tiers VANCOUVER (C.-B.), […]
January 13, 2021
News
Numinus Wellness Forges Forward into Psychedelic Discovery Research with the Orbitrap Exploris 120 Mass Spectometer
Cliquez ici pour la version française Acquisition of industry-leading instrument by Thermo Fisher Scientific will significantly advance psychedelic research and accelerate third-party standardized testing capabilities VANCOUVER, BC, January 13, 2021 – Numinus […]
January 13, 2021
News
FR: Numinus et Optimi Health signent une entente de services de laboratoire pour faire progresser la recherche et le développement de produits psychédéliques
L’entente sera axée sur la mise au point de produits sûrs, efficaces et entièrement naturels pour le secteur émergent des psychédéliques VANCOUVER (C.-B.), le 6 janvier 2021 – Numinus Wellness Inc. (« Numinus […]
January 6, 2021
News
Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products
Cliquez ici pour la version française The agreement will focus on developing safe, effective, all-natural products for the emerging psychedelic industry VANCOUVER, BC, January 6, 2021 – Numinus Wellness Inc. ("Numinus" or the […]
January 6, 2021
News
Numinus Announces Closing of $17 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
Proceeds add to recently executed warrants and options of $8.9 million NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia, December 29, […]
December 29, 2020
News
FR: Une clinique montréalaise offre des thérapies assistées à la kétamine
99La substance est déjà largement utilisée dans le système de santé comme anesthésique et antidépresseur. Click here to read more.
December 19, 2020
News
Numinus Completes First Extraction of its Psilocybe Mushrooms
Canada’s first legal extraction by a public company is a landmark moment for the global psychedelic-assisted psychotherapies landscape VANCOUVER, BC, December 17, 2020 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a […]
December 17, 2020
News
Numinus Wellness Acquires Mindspace Wellbeing to Expand into Montreal
Numinus Wellness Inc. will soon have three locations in Montreal thanks to a recent acquisition. The Vancouver-based company announced this morning that it had acquired Mindspace Psychology Services Inc., a […]
December 15, 2020
News
FR: Numinus Wellness annonce son expansion nationale avec l'acquisition de Mindspace Wellbeing, un organisme de bien-être à services complets basé à Montréal et pionnier en matière de thérapies psychédéliques
Cette association renforce la position de Numinus en tant que chef de file dans le domaine de la psychothérapie et des solutions de santé psychédéliques fondées sur des données probantes […]
December 15, 2020
News
Numinus Wellness Announces National Expansion with Acquisition of Montreal-Based Mindspace Wellbeing, a Full-service Well-being Organization and Pioneer in Psychedelic Programming
Cliquez ici pour la version française The combination further enhances Numinus’ leadership position in evidence-based psychedelic-assisted psychotherapy and health solutions VANCOUVER (December 15, 2020) – Numinus Wellness Inc. ("Numinus" or the "Company") […]
December 15, 2020
News
Numinus Wellness commends Health Canada for its intent to make MDMA and psilocybin treatment available through the Special Access Programme
First-of-its-kind policy amendment will allow legal access to evidence-based treatments to those in need before formal drug approval VANCOUVER (December 11, 2020) – Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a […]
December 11, 2020
News
Numinus Wellness Inc. Announces an Increase to the Previously Announced Bought Deal Public Offering
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC, Dec. […]
December 7, 2020
News
Numinus Wellness Inc. Announces $10 Million Bought Deal Public Offering
  THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC, […]
December 7, 2020
News
Numinus and MAPS to Collaborate on MDMA Trial for PTSD
Vancouver-based firm Numinus announced yesterday it will collaborate with an arm of a longstanding non-profit association dedicated to the study of psychedelics in a first-of-its-kind clinical trial on MDMA. Numinus […]
December 3, 2020
News
Experts favour use of magic mushroom derivatives for research into mental health treatment
Educators, researchers see value in studying psilocybin’s effect treating mental health and addiction. Research utilizing magic mushroom derivatives has potential to help those suffering from mental health and addiction issues, […]
December 3, 2020
News
“Buried by Puppies Licking Your Face” (Canadian Firms Champion MDMA for PTSD)
Numinus Wellness Inc. and Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS PBC) have teamed up to petition Health Canada for approval to begin a trial using MDMA to treat PTSD. If […]
December 2, 2020
News
Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial
First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder VANCOUVER (December 2, 2020) – Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a […]
December 2, 2020
News
New Magic Mushroom Clinical Trial to Treat Addiction
Could magic mushrooms treat addiction? Vancouver based company Numinus has announced a new clinical trial of psilocybin-assisted psychotherapy to treat substance use disorders. Click here to read more.
November 23, 2020
News
Vancouver company announces clinical trial of psilocybin-assisted psychotherapy for substance use disorders
Vancouver-based Numinus Wellness Inc. has announced a 30-person clinical trial to establish the best practices for treating substance use disorders with psilocybin-assisted psychotherapy. According to a press release, the trial will […]
November 23, 2020
News
As medicine rediscovers magic mushrooms, a Montreal clinic says there's no time to waste
Researchers think magic mushrooms will be the future of health care. But how easily and fast regular people will be able to use them is another question -- one a […]
November 20, 2020
News
Down (the Rabbit Hole) and Out (of Addiction)
Magic Mushrooms, now legal in Oregon. have shown promise in treatment of addiction and depression. The question is — will the psychedelic approach ever be legal everywhere else? Numinus just announced its […]
November 18, 2020
News
Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders
Open-label clinical trial will evaluate and refine best practices for the delivery of psilocybin-assisted psychotherapy for participants with tobacco, stimulant, alcohol, and/or opioid disorders VANCOUVER, BC, Nov. 18, 2020 /CNW/ […]
November 18, 2020
News
Veterans Suffering from PTSD Find Relief Through Psilocybin
US Army Veteran Holly G. takes psilocybin to help make her combat-related PTSD more manageable. “Knowing that I can eat a mushroom and hit the reset button. It’s not a […]
October 29, 2020
News
Numinus Becomes The First Canadian Psychedelics Company To Legally Harvest Magic Mushrooms
Numinus CEO Payton Nyquvest and COO Michael Tan sat down with Forbes to discuss the company's harvest of psilocybe mushrooms, the first legal harvest in Canada since the 1970s. Click […]
October 29, 2020
News
Vancouver company completes first legal harvest of psilocybe mushrooms
Vancouver-based Numinus Wellness Inc. has completed its first harvest of psilocybe mushrooms, said to be the most common psilocybin-containing mushroom. Click here to read more.
October 29, 2020
News
Numinus Announces First Legal Harvest of Psilocybe Mushrooms
Vancouver-based health care company Numinus Bioscience has officially harvested the first legal batch of Psilocybe mushrooms in Canada by a public company. The announcement came only a few months after the company […]
October 24, 2020
News
Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe Mushrooms
Numinus Bioscience's developments include harvesting its first flush of Psilocybe mushrooms at its Health Canada licensed facility. VANCOUVER, BC, Oct. 22, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") […]
October 22, 2020
News
Numinus Appoints Multidisciplinary Global Leaders to its General Advisory Council
Advisors, including human performance expert Jamie Wheal and mental health advocate Ben Nemtin, join Numinus to help guide and inform company leadership VANCOUVER, BC, Oct. 14, 2020 /CNW/ - Recognized […]
October 14, 2020
News
How Numinus plans to support psychedelic assisted psychotherapy access to Canadians and beyond
Find out about the traction that psychedelic-assisted psychotherapy is gaining in the medical community and how Numinus plans to become a future potential supplier, scientific leader and clinical service provider. […]
October 13, 2020
News
Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory
Numinus progresses on its ecosystem approach to the ultimate delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies VANCOUVER, BC, Sept. 24, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") […]
September 24, 2020
News
Numinus Announces Listing of Warrants
VANCOUVER, BC, Sept. 18, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred around developing and supporting the safe, […]
September 18, 2020
News
Numinus Announces Closing of Oversubscribed $4.6 Million Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia, September 10, 2020, Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), is […]
September 10, 2020
News
Numinus Announces Filing of Final Short Form Prospectus for Offering of up to $4,000,000
Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies, is […]
September 3, 2020
News
Numinus and Together We Can Partner to Support Addiction Recovery and Mental Wellness
Numinus provides tailored treatments for clients of one of Canada's largest addiction treatment organizations VANCOUVER, BC, July 29, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a […]
July 29, 2020
News
Numinus Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to $4,050,000
VANCOUVER, BC, July 28, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, […]
July 28, 2020
News
Numinus Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to $4.05 Million
Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies, is […]
July 22, 2020
News
Company with Nanaimo lab gets federal approval for psychedelic drug research
Numinus' recently amended Health Canada licence allows the company to produce and extract psilocybin from mushrooms. The Nanaimo News Bulletin speaks with Numinus CEO Payton Nyquvest about the facility where […]
July 11, 2020
News
Conversations That Matter: Payton Nyquvest and Dr. Evan Wood
In a special to the Vancouver Sun, Simon Fraser University's Stu McNish speaks with Numinus CEO, Payton Nyquvest, and Chief Medical Officer, Dr. Evan Wood. Click here to read more.
July 3, 2020
News
Healthcare company Numinus believes psychedelic assisted therapy can improve mental health outcomes
Numinus CEO, Payton Nyquvest, and Chief Medical Officer, Dr. Evan Wood, discuss the potential of psychedelic-assisted psychotherapy to transform existing treatment models of mental health and addition - and how […]
June 24, 2020
News
Numinus announces Clinical Advisory Council to advance integrated wellness model
Advisors including Dr. Gabor Maté and Zach Walsh bring training and expertise in psychedelic-assisted therapy and mental health treatment VANCOUVER (June 24, 2020) – Numinus Wellness Inc. (“Numinus”; TSX-V: NUMI) […]
June 24, 2020
News
The business of producing psychedelics for science
The Daily Hive's Peter Smith speaks to Numinus CEO, Payton Nyquvest, about the business side of psychedelic-assisted therapy research and how Numinus's amended Health Canada licence puts them in a […]
June 23, 2020
News
Numinus licensed by Health Canada to extract and research psilocybin
Numinus CEO, Payton Nyquvest, and Chief Operating Officer, Michael Tan, spoke to Mugglehead about an amendment to the company's Health Canada licence which will allow them to produce and extract […]
June 12, 2020
News
Numinus Licencing Amendment: We Speak to the Team
Numinus Chief Operating Officer Michael Tan explains what the company's recent Health Canada licence amendment, which will allow them to produce and extract psilocybin from mushrooms, means for upcoming research. […]
June 12, 2020
News
Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms
Numinus becomes first publicly traded company in Canada approved to conduct research of this kind under a Health Canada licence VANCOUVER (June 11, 2020)—Numinus Wellness Inc. (TSX-V:NUMI - “Numinus” or the […]
June 11, 2020
News
Dr. Devon Christie, MD CCFP RTC IFMCP, joins Numinus as Medical Director
Medical doctor experienced in psychedelic assisted therapy and research to help advance Numinus protocol development and safe delivery of company’s patient-focused model VANCOUVER (June 3, 2020)—Dr. Evan Wood, Numinus Chief […]
June 3, 2020
News
Numinus Announces 2020 Operational Plans to Scale
Company gives guidance on near-term business objectives VANCOUVER (May 28th, 2020)— Numinus Wellness Inc. (“Numinus”), recently listed on the TSX Venture Exchange (TSX-V: NUMI), is pleased to report its near-term […]
May 28, 2020
News
Growing body of research shows patients with addiction, PTSD, and depression can benefit from psychedelic substances
In a discussion with CannCentral, Numinus Wellness Chief Medical Officer Dr. Evan Wood cautions that psychedelic assisted psychotherapy is not a cure for everybody—but trials have shown statistically significant results. […]
May 27, 2020
News
Dr. Gabor Maté, recognised physician and bestselling author, joins Numinus as Member of the Clinical Advisory Council
Maté will collaborate with the Numinus team in an advisory capacity and facilitate connections within the mental health community VANCOUVER (May 26th, 2020) – Numinus Wellness Inc. (“Numinus”; TSX-V: NUMI) […]
May 26, 2020
News
B.C. MP calls for legalization of some psychedelic drugs
CityNews TV talks to Numinus CEO Payton Nyquvest and advisor Gabor Mate about the future of psychedelic drugs as a potential treatment for mental health issues and addiction. Click here […]
May 23, 2020
News
Canada could regulate psychedelic therapy within few years, bets company
Numinus Wellness outlines where they see the business and the industry going following their public listing and announcement of Dr. Evan Wood as Chief Medical Officer. Click here to read […]
May 22, 2020
News
Psilocybin Alpha speaks with Dr. Evan Wood, CMO at Numinus
In an interview with Psilocybin Alpha, Numinus Chief Medical Officer Dr. Evan Wood outlines his thoughts on the future of psychedelics and society and where he sees Numinus’ role. Click […]
May 22, 2020
News
Vancouver-based Numinus Wellness hires addiction expert Dr. Evan Wood as chief medical officer
Numinus Chief Medical Officer Dr. Evan Wood needs no introduction to anyone who’s followed the harm-reduction movement in British Columbia over the past two decades. CannCentral details Dr. Wood’s expertise. […]
May 21, 2020
News
Dr. Evan Wood, recognized leader in the field of substance use research and treatment, joins Numinus as Chief Medical Officer
  Wood will lead research partnerships and the design of the Numinus patient-focused model VANCOUVER (May 21, 2020)— Numinus Wellness Inc. (“Numinus”) is pleased to announce the appointment of Dr. […]
May 21, 2020
News
Numinus Wellness Inc. commences trading on TSX Venture Exchange as NUMI
Integrated company to play a lead role in emerging psychedelic assisted therapy and research space VANCOUVER (May 20, 2020)—With momentum building for the use of psychedelic assisted therapies in addressing […]
May 20, 2020
News
Numinus Wellness Inc. (formerly Rojo Resources Ltd.) closes RTO with Salvation Botanicals LTD; to commence trading under "NUMI"
Numinus Wellness Inc. (formerly Rojo Resources Ltd., RJ:H) (“Numinus” or the “Company”) (TSXV: NUMI) is pleased to announce that it has closed its previously announced reverse take-over transaction with Salvation […]
May 15, 2020
News
Rojo Resources Ltd. announces the conditional approval of reverse take-over transaction with Salvation Botanicals Ltd.
Rojo Resources Ltd. (“Rojo” or the “Company”) (TSXV: RJ:H) is pleased to announce that it has received conditional approval from the TSX Venture Exchange (the “Exchange”) for its proposed reverse […]
May 4, 2020
News
Rojo Resources Ltd. announces closing of subscription receipt offering, Salvation Botanicals closes sidecar private placement - aggregate gross proceeds of $6,000,000 raised
VANCOUVER (March 10, 2020) — Rojo Resources Ltd. (“Rojo” or the “Company”) (TSXV: RJ:H) is pleased to announce that it has closed its previously announced private placement of subscription receipts. […]
March 10, 2020
News
End-to-end solution in psychedelic therapies establishes Numinus as leader in emerging space
VANCOUVER (February 24, 2020)—With momentum building for the use of psychedelic substances in the treatment of mental illness, addiction and trauma, Vancouver-based Numinus Wellness Inc. (“Numinus”) is now one of […]
February 24, 2020
News
Stacey Wallin & Payton Nyquvest - Waking up to a new consciousness
Payton Nyquvest and Stacey Wallin join Paul Austin to discuss their new project, Numinus, a company at the forefront of transformative changes in treating mental illness, addictions, trauma while addressing […]
December 10, 2019
Questions?
Call us toll-free 1-833-NUMINUS (686-4687)
crosschevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram